Tipping the GVH/GVL balance by targeting HIF1α. Cell Rep Med 2023 Nov 21;4(11):101295
Date
11/23/2023Pubmed ID
37992679Pubmed Central ID
PMC10694739DOI
10.1016/j.xcrm.2023.101295Scopus ID
2-s2.0-85177835310 (requires institutional sign-in at Scopus site)Abstract
Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.1.
Author List
Wu Y, Yu XZAuthors
Yongxia Wu PhD Assistant Professor in the Microbiology and Immunology department at Medical College of WisconsinXue-Zhong Yu MD Professor in the Microbiology and Immunology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Graft vs Host DiseaseHematopoietic Stem Cell Transplantation
Humans